UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the court | Quality of rulings and tight timeframes blamed for lack of appeals.
Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.
Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.
Precedential ruling finds errors in lower court’s findings in a case concerning medical devices | Earlier verdict has been vacated and remanded.
Judges partially overturn decision that ABS had failed to prove claims in Cytonome patent were invalid | PTAB and appeals court differ in interpretation of whether claims language had single or plural meaning.
Medical device company prevails after requesting inter partes reviews of three related patents | Patent Trial and Appeal Board finds obviousness in patents describing joint tissue repair and stabilisation.
Insulet has been awarded a preliminary injunction against EOFlow on its insulin patch pump products | Dispute and injunction come ahead of Medtronic’s planned $738m acquisition of EOFlow.
UN Committee on Racial Discrimination Calls for equitable access to vaccines, treatments, and health tech | Switzerland, Germany, UK, and US refusal to waive IP rights for COVID-19 vaccines 'aids discrimination against vulnerable communities'.
Dispute centred on alleged infringement of several patents related to keyhole surgery | Big pharma company acquired defendant firm in $3.4bn deal four years ago.
Win marks latest leg of cross-Atlantic litigation feud over devices that stop internal bleeding | Medical device maker garnered success against rival in the US and Germany but failed to secure an injunction in one European country.